Vivek Ramaswamy, a former hedge fund partner who went on to engineer one of the biggest biotech initial public offerings in history, has a new source of cash: his investment vehicle, Roivant Sciences, just raised $1.1 billion from investors including the Softbank Vision Fund and Dexcel Pharma.
from Forbes Real Time http://www.forbes.com/sites/matthewherper/2017/08/09/biotech-wunderkind-raises-1-1-billion-to-fund-pharma-startups/
via IFTTT
No comments:
Post a Comment